RBC Capital Remains a Buy on The Ensign Group (ENSG)
RBC Capital analyst Ben Hendrix reiterated a Buy rating on The Ensign Group yesterday and set a price target of $222.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Hendrix is a 4-star analyst with an average return of 5.4% and a 51.99% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, Acadia Healthcare, and CVS Health.
In addition to RBC Capital, The Ensign Group also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Care Facilities in a report issued on February 6. However, on the same day, Truist Financial maintained a Hold rating on The Ensign Group (NASDAQ: ENSG).
Based on The Ensign Group’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.36 billion and a net profit of $95.45 million. In comparison, last year the company earned a revenue of $1.13 billion and had a net profit of $79.69 million
Read More on ENSG:
Disclaimer & DisclosureReport an Issue
- Ensign’s Earnings Call Highlights Record Growth and Strength
- Ensign Group price target raised to $215 from $200 at Truist
- Ensign Group price target raised to $230 from $220 at UBS
- New ERP Rollout Poses Operational and Financial Reporting Risks for The Ensign in 2026
- Ensign Group reports Q4 adjusted EPS $1.82, consensus $1.77
